StockData

BioLineRx vs Xenetic Biosciences

BLRX and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLRX and XBIO compare

Xenetic Biosciences grew revenue faster over the last twelve months (33.3% versus −95.9% for BioLineRx).

Xenetic Biosciences scores higher on the StockData Score (12 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLRXXBIO
Size and price
Market cap–$3.8M
Share price$1.12$1.61
Change, 1 year−65.3%−38.1%
Change, 5 years−98.9%−88.9%
Beta (5Y)1.561.14
Employees202
StockData Score
Total score312 (better)
Valuation score03 (better)
Growth score12 (better)
Performance score02 (better)
Health score25 (better)
Dividend score00
Valuation
P/S–1.2×
P/B–0.6×
Fair value–$4.53
Margin of safety–64.4%
Growth
Revenue growth (TTM)−95.9%33.3% (better)
Revenue growth, 5Y average–46.8%
Profitability
Gross margin80.5%–
Operating margin−872%−81.0% (better)
Net margin–−75.9%
FCF margin−686%–
Return on equity–−47.0%
Return on invested capital−59.7%–
Financial health
Debt / equity0.33 (better)0.00
Interest coverage−8.0×–
Current ratio1.207.43 (better)
Altman Z-score–−37.70
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%6.5%
Held by insiders0.39%12.2%
Short interest, % of float–1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.